Those committed to the free exchange of scientific information have long complained about various restrictions on access to the FDA's pharmaceutical data and the resultant restrictions on open discourse. A review of open-government procedures and litigation at the FDA demonstrates that the need for transparency at the agency extend well beyond the reach of any clinical trial registry.
Peter Lurie and Allison Zieve,
Sometimes the Silence Can Be like the Thunder: Access to Pharmaceutical Data at the FDA,
69 Law and Contemporary Problems
Available at: http://scholarship.law.duke.edu/lcp/vol69/iss3/5